Growth Hormone Deficiency Market Summary
As per MRFR Analysis, the Growth Hormone Deficiency Market was valued at USD 4.45 Billion in 2023 and is projected to reach USD 6.42 Billion by 2032, growing at a CAGR of 3.58% from 2024 to 2032. The market is driven by advancements in diagnosis, increasing awareness, and expanding treatment options. The rising prevalence of growth hormone deficiency (GHD) and associated comorbidities such as obesity and diabetes are significant factors contributing to market growth. The pediatric segment dominated the market in 2022, while the subcutaneous route of administration led the market share. The Americas held the largest market share in 2022, attributed to developed healthcare infrastructure and technological advancements.
Key Market Trends & Highlights
The Growth Hormone Deficiency Market is witnessing notable trends and highlights.
- Market size in 2023: USD 4.45 Billion; projected to grow to USD 6.42 Billion by 2032.
- CAGR during 2024-2032: 3.58%; driven by increasing GHD prevalence and awareness.
- Pediatric growth hormone deficiency segment dominated the market in 2022.
- Subcutaneous administration route held the largest market share in 2022.
Market Size & Forecast
2023 Market Size: USD 4.45 Billion
2024 Market Size: USD 4.84 Billion
2032 Market Size: USD 6.42 Billion
CAGR (2024-2032): 3.58%
Largest Regional Market Share in 2022: Americas.
Major Players
Key companies include Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Novartis AG, Hoffmann-La Roche Ltd, and Merck KGaA.
“The growth hormone deficiency market is experiencing significant growth driven by advancements in diagnosis, increasing awareness, and expanding treatment options. Growing recognition of the impact of growth hormone deficiency on health, coupled with ongoing research and development efforts, positions this market for continued expansion in the foreseeable future.”
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The growth of the Growth Hormone Deficiency Market is expected to be driven by the increasing number of individuals suffering from growth hormone deficiency (GHD), rising awareness regarding the effectiveness of GH along with clinical trials focused on the safety and efficacy of GHD, and the changing lifestyle along with the growing prevalence of genetic disorders.
Growth Hormone Deficiency Trends
- Increasing prevalence of growth hormone deficiency fuels market growth
According to the published article in NCBI in March 2017, the estimated prevalence of GHD is approximately 2-3 in 10,000 population. GHD is caused by structural pituitary disease or cranial irradiation and occurs in the context of additional features of hypopituitarism. Pituitary adenomas are reported to cause adult-onset GHD followed by craniopharyngiomas, which accounts for approximately 57% of cases. In addition, childhood-onset growth hormone deficiency (CO-GHD) is one of the complex endocrine conditions that may have an impact throughout life, starting in childhood, and continuing till adulthood. Most of the CO-GH is reported to be congenital. The main co-morbidities and symptoms of GHD in adults and children are obesity, diabetes mellitus, hypertension, cerebrovascular diseases, cardiovascular diseases, and liver diseases. This increasing morbidity of GH disease in both children and adults is expected to drive the growth of the growth hormone deficiency market.
Growth Hormone Deficiency Segment Insights
Growth Hormone Deficiency Brand Insights
The Growth Hormone Deficiency Market segmentation, based on brand, includes Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others. The others segment held the majority share in the market in 2022. Others include Nutropin, Jintropin, Growject, Hormotrop, Tev-tropin, Nutropinaq, Zomacton, and Eutropin.
Growth Hormone Deficiency Application Insights
The Growth Hormone Deficiency Market segmentation, based on application, includes paediatric growth hormone deficiency, idiopathic short stature, small for gestational age, turner syndrome, adult growth hormone deficiency, prader-willi syndrome, and others. The paediatric growth hormone deficiency segment dominated the market in 2022. Growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the US, according to the American Academy of Paediatrics.
Figure 2: Growth Hormone Deficiency Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Growth Hormone Deficiency Route of Administration Insights
The Growth Hormone Deficiency Market segmentation, based on route of administration, subcutaneous, intramuscular, and intravenous. The subcutaneous segment dominated the market in 2022. The segment growth is increasing as it leads to a significant rise in growth rates in patients and a low incidence of antibody development. The majority of the GHD drugs are administered through subcutaneous ROA (Route of Administration). For instance, brands such as Norditropin, Genotropin, Humatrope, Omnitrope, Nutropin, and Saizen are administered subcutaneously.
Growth Hormone Deficiency Distribution Channel Insights
The Growth Hormone Deficiency Market segmentation, based on distribution channel, includes hospital pharmacies, retail pharmacies, clinics, and e-commerce websites. The hospital pharmacies segment dominated the market in 2022. Recombinant growth hormone is a prescription medication made available only with a prescription of a physician. Moreover, most hospitals have a policy that patients ought to buy medications prescribed by the practitioners from their premises only. Additionally, high investments by governments for the development of advanced healthcare centers and hospitals in various countries are also contributing to the distribution of growth hormone medicines through hospital pharmacies.
Growth Hormone Deficiency Regional Insights
By Region, the study segments the market into Americas, Europe, Asia-Pacific, and Middle East & Africa. The Americas growth hormone deficiency market accounted for the largest market share in 2022. Key factors attributed to its large share include developed healthcare infrastructure, increasing technological advancement, and the presence of many market players in the region.
Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: GROWTH HORMONE DEFICIENCY MARKET BY REGION 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe growth hormone deficiency market accounted for the second-largest market share due to growing prevalence of GHD individuals, and the rising awareness of treatment. Furthermore, the Germany growth hormone deficiency market is attributed to hold the largest market share, and the France growth hormone deficiency market is projected be the fastest growing market in the Europe region.
The Asia-Pacific growth hormone deficiency market is expected to be the fastest growing from 2023 to 2032 due to growing advancement in treatment, increasing funds in research activities, and rising prevalence of GHD. Moreover, China growth hormone deficiency market accounted to hold the largest market share, and the India growth hormone deficiency market is projected to be the fastest growing market in the Asia-Pacific region.
Growth Hormone Deficiency Key Market Players & Competitive Insights
The Growth Hormone Deficiency Market is characterized by many global, regional, and local vendors catering to the demand created by a large patient pool suffering from growth hormone deficiency. The market is highly competitive, with players competing and collaborating to gain a substantial market share in the Growth Hormone Deficiency Market. Expansion into newer untapped markets, novel product launches, rising collaborative agreements, and decisions undertaken to achieve operational efficiency are key factors that aid market growth. Our analysis revealed that market players had adopted different strategies and innovative research & development techniques to expand their business and secure their position in the Growth Hormone Deficiency Market. In recent years, strategic collaborations by major players for product development and regional expansion into untapped markets have been used as a strategy to obtain operational efficiency.
Merck KGaA (Merck) is a leading pharmaceutical company that offers several products sub grouped into three segments—healthcare, life sciences, and performance materials. The company delivers innovative health solutions and provides breakthrough solutions and technologies. It has expanded its global footprint through several mergers & acquisitions, such as the acquisition of Millipore and Sigma. EMD Sereno, Inc. is a biopharmaceutical business of Merck that is engaged in developing the Somatropin injection. It works with clients and in more than 140 countries to provide innovative healthcare products globally.
Key Companies in the Growth Hormone Deficiency market includes
- Novo Nordisk A/S (Denmark)
- Eli Lily and Company (Netherlands)
- Novartis AG (Switzerland)
- Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Ispen Pharma (Switzerland)
- Ferring Pharmaceuticals (Switzerland)
- Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China)
Growth Hormone Deficiency Industry Developments
- In September 2020, Novo Nordisk received US Food and Drug Administration approval for Sogroya (somapacitan). The drug is used in the treatment of adults suffering from growth hormone deficiency.
- In February 2018, Merck expanded its manufacturing & distribution center in India by investing EUR 16.6 Billion.
- In January 2018, Ferring Pharmaceuticals received FDA approval for Zomacton (somatropin) injection used for adults suffering from growth hormone deficiency.
Growth Hormone Deficiency Segmentation
Growth Hormone Deficiency Brand Outlook
Growth Hormone Deficiency Application Outlook
- Paediatric Growth Hormone Deficiency
- Small for Gestational Age
- Adult Growth Hormone Deficiency
Growth Hormone Deficiency Route of Administration Outlook
Growth Hormone Deficiency Distribution Channel Outlook
Growth Hormone Deficiency Regional Outlook
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 4.45 Billion |
| Market Size 2024 |
USD 4.84 Billion |
| Market Size 2032 |
USD 6.42 Billion |
| Compound Annual Growth Rate (CAGR) |
3.58% (2024-2032) |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Historical Data |
2019 to 2022 |
| Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Brand, Application, Route of Administration, Distribution Channel, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Ispen Pharma (Switzerland), Ferring Pharmaceuticals (Switzerland), AnkeBio Co., Ltd (China), and Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China) |
| Key Market Opportunities |
· Strong pipeline of hormonal drugs· Easy availability of pharma drugs on E-commerce platforms |
| Key Market Drivers |
· Increasing cost of GHD· Increasing counterfeit products for GHD treatment· Rising number of strategic initiatives |
Frequently Asked Questions (FAQ) :
The Growth Hormone Deficiency Market is anticipated to reach 6.42 Billion during the forecast period of 2023-2032.
The US is expected to hold a 90.15% share of the North America market.
The growth hormone deficiency market is expected to grow at an 8.86% CAGR during the forecast period from 2023 to 2032.
The Americas region market is estimated to hold the largest market share in growth hormone deficiency market.
The key players include Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), and Novartis AG (Switzerland).
The hospitals pharmacies segment led the growth hormone deficiency market.
